AI-Driven Drug Discovery Could Shift Medicine From Trial-and-Error to Engineering
@NoPriorsPodcast · · 35-second read
Top comments from YouTube.
This story is from November 12, 2026. For the latest, see today's news.
November 12, 2026 · Emerging AI
In a podcast interview, Max Jaderberg, president of Isomorphic Labs, discusses how artificial intelligence is reshaping pharmaceutical drug discovery. Historically, the field has relied on expensive, time-consuming empirical testing. Isomorphic aims to move discovery onto computers by building AI models that predict molecular outcomes with high accuracy, reducing the need for physical trial and error.
Jaderberg points to AlphaFold—DeepMind's AI model that predicted protein structures—as proof that deep learning can generalize effectively in biology. He describes how AI models compound learnings as they scale, improving success rates and accelerating clinical trials. The approach could reduce or eliminate animal testing through computational simulations.
Isomorphic is developing disease-agnostic drug design engines that can optimize molecules across different targets and modalities. Jaderberg also discusses how AI-driven optimization could enable multidrug combinations that address complex biological pathways, potentially extending both human lifespan and healthspan.
This is an AI-written summary. The original reporting belongs to @NoPriorsPodcast. How we write these · Spot a mistake?
Get the AI brief every morning.
The five AI stories that matter each morning: startups, money, jobs, tech and what's coming next. Free, and one click to unsubscribe. See our Privacy Policy.